Literature DB >> 10516062

Mutant cells selected during persistent reovirus infection do not express mature cathepsin L and do not support reovirus disassembly.

G S Baer1, D H Ebert, C J Chung, A H Erickson, T S Dermody.   

Abstract

Persistent reovirus infections of murine L929 cells select cellular mutations that inhibit viral disassembly within the endocytic pathway. Mutant cells support reovirus growth when infection is initiated with infectious subvirion particles (ISVPs), which are intermediates in reovirus disassembly formed following proteolysis of viral outer-capsid proteins. However, mutant cells do not support growth of virions, indicating that these cells have a defect in virion-to-ISVP processing. To better understand mechanisms by which viruses use the endocytic pathway to enter cells, we defined steps in reovirus replication blocked in mutant cells selected during persistent infection. Subcellular localization of reovirus after adsorption to parental and mutant cells was assessed using confocal microscopy and virions conjugated to a fluorescent probe. Parental and mutant cells did not differ in the capacity to internalize virions or distribute them to perinuclear compartments. Using pH-sensitive probes, the intravesicular pH was determined and found to be equivalent in parental and mutant cells. In both cell types, virions localized to acidified intracellular organelles. The capacity of parental and mutant cells to support proteolysis of reovirus virions was assessed by monitoring the appearance of disassembly intermediates following adsorption of radiolabeled viral particles. Within 2 h after adsorption to parental cells, proteolysis of viral outer-capsid proteins was observed, consistent with formation of ISVPs. However, in mutant cells, no proteolysis of viral proteins was detected up to 8 h postadsorption. Since treatment of cells with E64, an inhibitor of cysteine-containing proteases, blocks reovirus disassembly, we used immunoblot analysis to assess the expression of cathepsin L, a lysosomal cysteine protease. In contrast to parental cells, mutant cells did not express the mature, proteolytically active form of the enzyme. The defect in cathepsin L maturation was not associated with mutations in procathepsin L mRNA, was not complemented by procathepsin L overexpression, and did not affect the maturation of cathepsin B, another lysosomal cysteine protease. These findings indicate that persistent reovirus infections select cellular mutations that affect the maturation of cathepsin L and suggest that alterations in the expression of lysosomal proteases can modulate viral cytopathicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516062      PMCID: PMC112988          DOI: 10.1128/JVI.73.11.9532-9543.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Protease cleavage of reovirus capsid protein mu1/mu1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subvirion particle.

Authors:  K Chandran; M L Nibert
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

Review 2.  Molecular mechanisms of persistent infection by reovirus.

Authors:  T S Dermody
Journal:  Curr Top Microbiol Immunol       Date:  1998       Impact factor: 4.291

3.  Mutations in reovirus outer-capsid protein sigma3 selected during persistent infections of L cells confer resistance to protease inhibitor E64.

Authors:  G S Baer; T S Dermody
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Efficiency of viral entry determines the capacity of murine erythroleukemia cells to support persistent infections by mammalian reoviruses.

Authors:  J D Wetzel; J D Chappell; A B Fogo; T S Dermody
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  Reovirus: evidence for a second step in the intracellular uncoating and transcriptase activation process.

Authors:  J Borsa; M D Sargent; P A Lievaart; T P Copps
Journal:  Virology       Date:  1981-05       Impact factor: 3.616

6.  Reovirus variants selected during persistent infections of L cells contain mutations in the viral S1 and S4 genes and are altered in viral disassembly.

Authors:  J D Wetzel; G J Wilson; G S Baer; L R Dunnigan; J P Wright; D S Tang; T S Dermody
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

7.  Abnormal glycosylation of procathepsin L due to N-terminal point mutations correlates with failure to sort to lysosomes.

Authors:  R L Chapman; S E Kane; A H Erickson
Journal:  J Biol Chem       Date:  1997-03-28       Impact factor: 5.157

8.  No role for pepstatin-A-sensitive acidic proteinases in reovirus infections of L or MDCK cells.

Authors:  S Kothandaraman; M C Hebert; R T Raines; M L Nibert
Journal:  Virology       Date:  1998-11-25       Impact factor: 3.616

9.  Monoclonal antibodies to reovirus sigma 1 and mu 1 proteins inhibit chromium release from mouse L cells.

Authors:  J W Hooper; B N Fields
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

10.  Cleavage susceptibility of reovirus attachment protein sigma1 during proteolytic disassembly of virions is determined by a sequence polymorphism in the sigma1 neck.

Authors:  J D Chappell; E S Barton; T H Smith; G S Baer; D T Duong; M L Nibert; T S Dermody
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

View more
  35 in total

1.  Complete in vitro assembly of the reovirus outer capsid produces highly infectious particles suitable for genetic studies of the receptor-binding protein.

Authors:  K Chandran; X Zhang; N H Olson; S B Walker; J D Chappell; T S Dermody; T S Baker; M L Nibert
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Sites and determinants of early cleavages in the proteolytic processing pathway of reovirus surface protein sigma3.

Authors:  Judit Jané-Valbuena; Laura A Breun; Leslie A Schiff; Max L Nibert
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  A single mutation in the carboxy terminus of reovirus outer-capsid protein sigma 3 confers enhanced kinetics of sigma 3 proteolysis, resistance to inhibitors of viral disassembly, and alterations in sigma 3 structure.

Authors:  Gregory J Wilson; Emma L Nason; Charles S Hardy; Daniel H Ebert; J Denise Wetzel; B V Venkataram Prasad; Terence S Dermody
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

4.  Impact of host proteases on reovirus infection in the respiratory tract.

Authors:  Rachel M Nygaard; Joseph W Golden; Leslie A Schiff
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

5.  Transport to late endosomes is required for efficient reovirus infection.

Authors:  Bernardo A Mainou; Terence S Dermody
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

6.  Gene-specific inhibition of reovirus replication by RNA interference.

Authors:  Takeshi Kobayashi; James D Chappell; Pranav Danthi; Terence S Dermody
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

7.  Reovirus variants selected for resistance to ammonium chloride have mutations in viral outer-capsid protein sigma3.

Authors:  Kimberly M Clark; J Denise Wetzel; Yingqi Gu; Daniel H Ebert; Stephanie A McAbee; Emily K Stoneman; Geoffrey S Baer; Yuwei Zhu; Gregory J Wilson; B V V Prasad; Terence S Dermody
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

8.  Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis.

Authors:  Maya Shmulevitz; Shashi A Gujar; Dae-Gyun Ahn; Adil Mohamed; Patrick W K Lee
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

9.  Identification of functional domains in reovirus replication proteins muNS and mu2.

Authors:  Takeshi Kobayashi; Laura S Ooms; James D Chappell; Terence S Dermody
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

10.  Strategy for nonenveloped virus entry: a hydrophobic conformer of the reovirus membrane penetration protein micro 1 mediates membrane disruption.

Authors:  Kartik Chandran; Diane L Farsetta; Max L Nibert
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.